Trending...
- Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
- Still Using Ice? FrostSkin Reinvents Hydration
- High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
RALEIGH N.C. & DURHAM, N.C.--(BUSINESS WIRE)--NovaQuest Private Equity ("NovaQuest") today announced its strategic growth equity investment in Pro-ficiency, LLC ("Pro-ficiency"), a leading provider of tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
Based in Durham, NC, Pro-ficiency provides innovative, virtual simulation training and HR compliance solutions for clinical trials, supported by original content creation and analytics services. Leading pharmaceutical companies engage Pro-ficiency to deploy customized, study-specific training solutions that improve learning retention and strengthen compliance among investigators and site staff. The company's platform also provides sponsors and CROs with real-time analytics that help to predict and avoid study errors and protocol violations, ultimately reducing the time, cost, and failure points of clinical trials. This integrated suite of services provides a compelling value proposition to its pharmaceutical customers.
"Pro-ficiency is excited to partner with NovaQuest, a firm with unparalleled global pharma and life sciences relationships and a proven track record of successfully supporting market-leading businesses in their next phase of growth," said David Hadden, Co-Founder of Pro-ficiency. "With NovaQuest's growth equity investment, Pro-ficiency is well-funded to continue changing the paradigm of clinical trial training."
More on ncarol.com
- Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
- DASH Carolina RDU Sets the Pace in 2025 with Record-Breaking Sales and Team Excellence
- Wespor Business Launches AI Voice and Chat Agents to Help Triangle Small Businesses Capture Missed Leads
- America's Boating Club Ushers in New Board at Change of Watch
- FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
"Our customers are developing innovative products that require rigorous compliance across increasingly complex and global trials," said JoAnne Schaberick, Co-Founder of Pro-ficiency. "NovaQuest's expertise in life sciences and clinical trials will be invaluable as we continue to expand our team and offering to consistently surpass expectations and meet the needs of our valued customers."
"Dave and JoAnne are pioneers in the use of simulation-based training to improve healthcare. They have done an outstanding job developing a platform that addresses a critical, unmet need for better clinical trial training solutions," said Michael Sorensen, Partner at NovaQuest. "We look forward to supporting the Pro-ficiency team as it meets unprecedented demand for its mission-critical clinical trial training solutions."
Wyrick Robbins served as legal advisor to Pro-ficiency, and Smith Anderson served as legal advisor to NovaQuest. Deal terms were not announced.
About Pro-ficiency:
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. For more information, please visit www.pro-ficiency.com.
More on ncarol.com
- $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
- CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
- PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
- Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
- From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
About NovaQuest Private Equity:
NovaQuest Private Equity is a leading investor in technology and services companies in the life sciences and healthcare sectors. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital and operational leverage in partnership with strong management teams. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
- Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
- Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
- Angels Of Dirt Premieres on Youtube, Announces Paige Keck Helmet Sponsorship for 2026 Season
- Still Using Ice? FrostSkin Reinvents Hydration
- Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
- Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
- General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
- Unseasonable Warmth Triggers Early Pest Season Along I-5 Corridor
- Bug Busters Expands Service Footprint With New Carrollton, Georgia Branch
- Why KULR Could Be a Quiet Enabler of Space-Based Solar Power (SBSP) Over The Long Term: KULR Technology Group, Inc. (NY SE American: KULR)
- Why Finland Had No Choice But to Legalize Online Gambling
- High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
- iFLO Pro Launches Its Groundbreaking iFLO Pro Mini At The 2026 AHR Expo In Las Vegas
- TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
- Diveroli Investment Group Files 13D in PetMed Express, Highlights Strategic Value, Asset Floor, and Multiple Takeover Pathways
- Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
- The Quasar Dipole Phenomenon is likely just a complex systematics artifact
- The Rise of Comprehensive Home Water Treatment Systems
- Yazaki Innovations to Introduce First-Ever Prefabricated Home Wiring System to U.S. Residential Market in 2026